Frequency of factor VIII inhibitor using the Nijmegen methodology in patients with hemophilia
Main Article Content
Abstract
One of the biggest complications of a hemophiliac patient is the development of inhibitors and it is a challenge for treating physicians, therefore, its early detection and the search for a test that supports the diagnosis for the benefit of the patient is of great importance. . importance for adequate treatment. The presence of inhibitors is associated with morbidity accompanied by hemorrhagic complications and low quality of life. The objective of the research was to determine inhibitors in hemophilic patients using the Nijmegen test, as a technique that allows detecting low levels of inhibitors. The methodology was descriptive and transversal. The frequency of FVIII inhibitor was 11.9% in 118 patients who underwent testing. 64.2% had a low response with a titer less than 5 BNU and 35.7% had a high response with a response greater than 5 BNU. The age group was adolescent 36%, preschool 29%, school 21% and finally adult 14%. It is concluded that there is a relationship between the time of exposure to treatment and the inhibitor response (p > 0.01) and it is recommended to carry out more research in the community with this pathology and study other variables that intervene in the development. of inhibitors
Article Details
Issue
Section
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
References
Álvarez de León, LM, López, MJ. 2015. Determinación de inhibidores de factor VIII en pacientes con hemofilia A. Guatemala pediátrica 1(1):47–52.
Arias M. 2016. Actualización en el diagnóstico inhibidor de factor VIII. (simposio). Disponible: https://www.sah.org.ar/revistasah/numeros/24-vol-20-congre-2016.pdf
Balkaransingh P, Young G. 2018. Novel therapies and current clinical progress in hemophilia A. Ther Adv Hematol. 9(2):49–61. doi:10.1177/2040620717746312
Carcao M, Goudemand J. 2018. Los inhibidores de la hemofilia: información básica. 5a ed. Tratamiento de la hemofilia No. 7. Montreal (QC): Federación Mundial de Hemofilia.
Chalmers EA, Alamelu J, Collins PW, Mathias M, Payne J, Richards M, Tunstall O, Williams M, Palmer B, Mumford A. 2018. Intracranial haemorrhage in children with inherited bleeding disorders in the UK 2003-2015: A national cohort study. Haemophilia. 24(4):641–647. doi:10.1111/hae.13461
Dou X, Liu W, Poon MC, Zhang X., Wu J, Zeng X, Wu R, Hu Q, Li C, Wang X et al. 2021. Patients with haemophilia A with inhibitors in China: a national real-world analysis and follow-up. Br J Haematol. 192(5):900–908. doi:10.1111/bjh.17322
Eckhardt CL, van Velzen AS, Peters M, Astermark J, Brons PP, Castaman G, Cnossen MH, Dors N, Escuriola-Ettingshausen C, Hamulyak K, et al. 2013. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood. doi:10.1182/blood-2013-02.
FMH [Federación Mundial de Hemofilia]. 2021. El informe del sondeo mundial anual 2020. Montreal (QC): Federación Mundial de Hemofilia.
Gandhi T, Lawler P, Foxton E, Chowdary P, Riddell A. 2020. Clinical utility of sample preheat treatment in a modified Nijmegen-Bethesda assay (mNBA) for inhibitor monitoring in congenital and acquired haemophilia A: A singlecentre four-year experience. Haemophilia. 26(6): e300–e307. doi:10.1111/hae.14090
Gouw SC, Van Den Berg H, Fischer K, Auerswald G, Carcao M, Chalmers E, Herv´ H, Chambost H, Kurnik K, Liesner R, et al. 2013. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood. 121(20):4046–4055. doi:10.1182/blood-2012-09.
Haya S. 2019. Prophylactic treatment in hemophilic patients with inhibitors. Blood Coagulation and Fibrinolysis. 30(1S): S14–S18. doi:10.1097/MBC.0000000000000823
Hwang SH, Lim JA, Kim MJ, Kim HC, Lee HW, Yoo KY, You CW, Lee KS, Kim HS. 2012. Profiling of differentially expressed genes in haemophilia A with inhibitor. Haemophilia. 18(3). doi:10.1111/j.1365-2516.2011.02702.x
Iorio A, Stonebraker JS, Chambost H, Makris M, Coffin D, Herr C, Germini F, Stonebraker JS, Byams V, El-Ekiaby M, et al. 2019. Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries. Ann Intern Med. 171(8):542–546. doi:10.7326/M19-1208
Ketteler C, Hoffmann I, Davidson S, Chen D, Tiede A, Richter N. 2022. Impact of different factor VIII inhibitor kinetic profiles on the inhibitor titer quantification using the modified Nijmegen–Bethesda assay. Res Pract Thromb Haemost. 6(8). doi:10.1002/rth2.12799.
Key NS. 2004. Inhibitors in congenital coagulation disorders. Br J Haematol. 127(4):379–391. doi:10.1111/j.1365-2141.2004.05168.x
Kitchen S, Mccraw A, Echenagucia M. 2010. Diagnóstico de la hemofilia y otros trastornos de la coagulación: manual de laboratorio. 2a ed. Montreal (QC): Federación Mundial de Hemofilia.
Lim MY, Cheng D, Recht M, Kempton CL, Key NS. 2020. Inhibitors and mortality in persons with nonsevere hemophilia A in the United States. Blood Adv. 4(19):4739–4747. doi:10.1182/bloodadvances.2020002626.
Mardones M, Pérez Pazmiño F, Pino Bedón M. 2017. Detección de inhibidores de factor VIII y IX en pacientes que reciben factores de coagulación liofilizados como profilaxis o tratamiento. Rev Ecuat Med Cienc Biol. 38(2):121–126. doi:10.26807/remcb.v38i2.545
Meijer P, Peyvandi F, Young G, Pruthi R, de Lima Montalvão S, Kitchen S. 2023. International Council for Standardization in Haematology recommendations for laboratory measurement of factor VIII and FIX type I inhibitors. Int J Lab Hematol. 45(4):413–424. doi:10.1111/ijlh.14109
MSP [Ministerio de Salud Pública]. 2012. Criterios de inclusión de enfermedades consideradas catastróficas, raras y huérfanas para beneficiarios del bono Joaquín Gallegos Lara. Acuerdo Ministerial No. 00001829. Quito (Ecuador): Ministerio de Salud Pública.
MSP [Ministerio de Salud Pública]. 2016. Diagnóstico y tratamiento de la hemofilia congénita: guía práctica clínica. 1a ed. Quito (Ecuador): Dirección Nacional de Normatización, Ministerio de Salud Pública.
MSP [Ministerio de Salud Pública]. 2018. Pacientes con hemofilia destacan mejoras en atención sanitaria. MSP Noticias Destacadas [Internet]. [consultado 2024 Nov 14] Disponible en: https://www.salud.gob.ec/pacientescon-hemofilia-destacan-mejoras-en-atencion-sanitaria/#
MSP [Ministerio de Salud Pública]. 2022. MSP realiza nueva adquisición de medicamentos para hemofilia. MSP Noticias Destacadas [Internet]. [consultado 2024 Nov 14] Disponible en: https://www.salud.gob.ec/msprealiza-nueva-adquisicion-de-medicamentos-para-hemofilia/
Müller J, Pekrul I, Pötzsch B, Berning B, Oldenburg J, Spannagl M. 2019. Laboratory monitoring in emicizumabtreated persons with hemophilia A. Thromb Haemost. 119(9):1384–1393. doi:10.1055/s-0039-1692427
Peyvandi F, Kavakli K, El-Beshlawy A, Rangarajan S. 2022. Management of haemophilia A with inhibitors: A regional cross-talk. Haemophilia. 28(6):950–961. doi:10.1111/hae.14638
Pratt KP, Arruda VR, Lacroix-Desmazes S. 2021. Inhibitors—Recent insights. Haemophilia. 27(S3):28–36. doi:10.1111/hae.14077
Rezende SM, Neumann I, Angchaisuksiri P, Awodu O, Boban A, Cuker A, Curtin JA, Fijnvandraat K, Gouw SC, Gualtierotti R, et al. 2024. International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital hemophilia A and B based on the Grading of Recommendations Assessment, Development, and Evaluation methodology. J Thromb Haemost. 22(9):2629–2652. doi:10.1016/j.jtha.2024.05.026
Da Silva Pinto María, da Silva Liliana, Ferreira De Carvalho F. 2022. Hemofilia A congénita con inhibidores e inducción de inmunotolerancia en niños y adolescentes jóvenes: ¿podría Brasil ser un ejemplo para otros países? Rev Hematol 26(1)–10. https://revistahematologia.com.ar/index.php/Revista/article/view/413
Valke LLFG, Verhagen MJA, Mulders BTPM, Polenewen R, Blijlevens NMA, Jansen JH, Mansouritorghabeh H, Elsheikh E, Reipert BM, Turecek PL, et al. 2023. The Nijmegen ultra-sensitive Bethesda Assay detects very low-titer factor VIII inhibitors in patients with congenital and acquired hemophilia A. Thromb Res. 231:112–120. doi:10.1016/j.thromres.2023.10.007
Villarreal-Martínez L, García-Chávez J, Sánchez-Jara B, Moreno-González AM, Soto-Padilla J, Aquino-Fernández E, Paredes-Aguilera R, Maldonado-Silva K, Rodríguez-Castillejos C, González-Ávila AI, et al. 2020. Prevalence of inhibitors and clinical characteristics in patients with haemophilia in a middle-income Latin American country. Haemophilia. 26(2):290–297. doi:10.1111/hae.13951
Witmer C, Young G. 2013. Factor VIII inhibitors in hemophilia A: Rationale and latest evidence. Ther Adv Hematol. 4(1):59–72. doi:10.1177/2040620712464509.
Young G. 2019. How I treat children with haemophilia and inhibitors. Br J Haematol. 186(3):400–408. doi:10.1111/bjh.15942.